Holen Sie sich die Stockscreener-App
32.31
0.80%
-0.26
Handel nachbörslich:
32.31
Schlusskurs vom Vortag:
$32.57
Offen:
$32.69
24-Stunden-Volumen:
934.99K
Relative Volume:
0.69
Marktkapitalisierung:
$3.08B
Einnahmen:
$305.00K
Nettoeinkommen (Verlust:
$-328.98M
KGV:
-7.5753
EPS:
-4.2652
Netto-Cashflow:
$-309.60M
1W Leistung:
+0.91%
1M Leistung:
+11.64%
6M Leistung:
+106.19%
1J Leistung:
+79.60%
1-Tages-Spanne:
$32.29
$33.05
1-Wochen-Bereich:
$31.11
$33.29
52-Wochen-Spanne:
$9.90
$33.34
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
32.31 | 3.11B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Bestätigt | Wedbush | Outperform |
| 2025-12-03 | Eingeleitet | William Blair | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Understanding Momentum Shifts in (VRDN) - news.stocktradersdaily.com
Maverick Capital Ltd. Grows Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. $VRDN Shares Sold by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Has $6.77 Million Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Velan Capital Investment Management LP Makes New $1.21 Million Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Wedbush - MarketBeat
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating - marketscreener.com
VRDN: Wedbush Raises Price Target to $47 While Maintaining Outpe - GuruFocus
Viridian Therapeutics, Inc. $VRDN Stock Position Lifted by Marshall Wace LLP - MarketBeat
Diadema Partners LP Has $1.71 Million Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
With Viridian Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
What analysts say about Viridian Therapeutics Inc stockEarnings Growth Projections & High Return Capital Gain - earlytimes.in
Evaluating Viridian Therapeutics (VRDN) After William Blair’s New ‘Outperform’ Rating and Rising Investor Optimism - Sahm
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighWhat's Next? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 5, 2025 - BioSpace
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Why Viridian Therapeutics Inc. (1S1) stock fits value portfolios2025 AllTime Highs & Smart Allocation Stock Tips - Newser
Viridian Therapeutics stock hits 52-week high at 32.58 USD By Investing.com - Investing.com Canada
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Sahm
Viridian Therapeutics stock hits 52-week high at 32.58 USD - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How Viridian Therapeutics Inc. (1S1) stock gains from tech spendingMarket Sentiment Summary & Daily Chart Pattern Signal Reports - Newser
Can Viridian Therapeutics Inc. (1S1) stock retain market dominanceJuly 2025 Breakouts & Safe Entry Point Identification - Newser
Will William Blair’s Outperform Initiation Shift Viridian Therapeutics’ (VRDN) Narrative Among Institutional Investors? - Sahm
How analysts revise price targets for Viridian Therapeutics Inc. (1S1) stockJuly 2025 Final Week & High Yield Stock Recommendations - Newser
Is Viridian Therapeutics Inc. (1S1) stock suitable for passive index fundsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - Newser
William Blair Initiates Coverage of Viridian Therapeutics (VRDN) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN Stock News - GuruFocus
William Blair Initiates Viridian Therapeutics at Outperform - marketscreener.com
Why Viridian Therapeutics Inc. (1S1) stock is favored by hedge fundsTrade Exit Summary & Detailed Earnings Play Alerts - Newser
Loomis Sayles & Co. L P Sells 31,884 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Avoiding Lag: Real-Time Signals in (VRDN) Movement - news.stocktradersdaily.com
Geode Capital Management LLC Purchases 20,089 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Will Viridian Therapeutics Inc. stock attract more institutional investorsTrade Exit Summary & Real-Time Volume Analysis - BỘ NỘI VỤ
Viridian Therapeutics (VRDN): Revisiting Valuation After Analyst Upgrades and Robust Revenue Growth - Sahm
Will Viridian Therapeutics Inc. stock continue upward momentumMarket Risk Summary & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Intech Investment Management LLC Reduces Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sets New 1-Year HighShould You Buy? - MarketBeat
Truist Securities Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Truist Securities Initiates Coverage on VRDN with Buy Rating | V - GuruFocus
Truist Securities initiates coverage on Viridian Therapeutic stock with Buy rating - Investing.com Canada
Why Viridian Therapeutics Shares Are Climbing Higher - TipRanks
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues - simplywall.st
Viridian Therapeutics Inc. (VRDN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Viridian Therapeutics stock hits 52-week high at $30.15 By Investing.com - Investing.com Nigeria
Viridian Therapeutics stock hits 52-week high at $30.15 - Investing.com India
Discipline and Rules-Based Execution in VRDN Response - news.stocktradersdaily.com
Is Viridian Therapeutics Inc. stock attractive for hedge fundsDollar Strength & Stepwise Entry and Exit Trade Signals - newser.com
Is Viridian Therapeutics Inc. stock cheap at current valuation2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
How Viridian Therapeutics Inc. (1S1) stock compares with top peersJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):